

## References

L-28

1. MacDonald I, Murray A, Healey G, et al. Application of a high throughput method of biomarker discovery to improvement of the EarlyCDT®-Lung Test. *PLoS One*. 2012; 7(12):e51002.
2. Chapman C, Healey G, Murray A, et al. EarlyCDT®-Lung test: Improved clinical utility through additional autoantibody assays. *Tumour Biology*. 2012; 35(5):1319-1326.
3. Müller V, Riethdorf S, Rack B, et al. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: The DETECT study. *Breast Cancer Research*. 2012; (14): R118.
4. Daumerie C, Maiter D, and Gruson D. Serum calcitonin estimation in medullary thyroid cancer: Basal or stimulated levels? *Thyroid Research*. 2013; 6(Suppl.1):S4.
5. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer. American Urological Associations (AUA) Guideline. 2013.
6. Ringel MD, Nabhan F. Approach to follow-up of the patient with differentiated thyroid cancer and positive anti-thyroglobulin antibodies. *Journal of Clinical Endocrinology Metab*. 2013; 98(8):3104-3110.
7. Kamat A, Dickstein R, Messetti F, et al. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guerin therapy for bladder cancer: Results of a prospective trial. *Journal of Urology*. 2012; 187(3):862-867.
8. Kamat A, Hegarty P, Gee J, et al. ICUD-EAU International consultation on bladder cancer 2012: Screening, diagnosis, and molecular markers. *European Urology*. 2013; 63:4-15.
9. Babacan A, Kizilaslan C, Gun I, et al. CA 125 and other tumor markers in uterine leiomyomas and their association with lesion characteristics. *Int J Clin Exp Med*. 2014; 7(4):1078-1083.
10. Kaufman P, Bloom K, Burris H, et al. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. *Cancer*. 2014.
11. American Society of Clinical Oncology. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *Journal of Clinical Oncology*. 2013; 31(13):3397-4013.
12. Agency for Healthcare Research and Quality (AHRQ). Multigene panels in prostate cancer risk assessment. *Agency for Research and Quality*. 2012.
13. Ip S, Dahabreh IJ, Chung M, et al. An evidence review of active surveillance in men with localized prostate cancer. *Agency for Research and Quality*. 2014.
14. Klein E, Cooperberg M, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. *European Urology*. 2014; 550-560.
15. Knezevic D, Goddard A, Natraj N, et al. Analytical validation of the oncotype dx prostate cancer assay- A clinical RT-PCR assay optimized for prostate needle biopsies. *BMC Genomics*. 2013; 14:690.

16. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Prostate cancer. Version 1.2015.
17. Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions of adjuvant systemic therapy for women with early stage invasive breast cancer: American Society of Oncology clinical practice guideline. *J Clin Oncol*. 2016; (34).
18. National Comprehensive Cancer network (NCCN). Clinical practice guidelines in oncology. bladder cancer. Version 1.2013.
19. Chen Y, Qu H, Jian M, et al. High level of serum AFP is an independent negative prognostic factor in gastric cancer. *Int J Biol Markers*. 2015; 30(4): e387-e393.
20. Bie Y, Zhang Z. Diagnostic value of serum HE4 in endometrial cancer: A meta-analysis. *World J Surg Oncol*. 2014; 1-6.
21. Geng B, Liang M, Ye X, et al. Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. *Molecular and Clinical Oncology*. 2015; 3(1): 232-236.
22. American Cancer Society. Tests for prostate cancer. May 15, 2017.
23. American Urological Association. PSA testing for the pre-treatment staging and post-treatment management of prostate cancer. 2013.
24. American Urological Association. Clinically localized prostate cancer: American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO)/ Society of Urologic Oncology (SUO) guideline. 2017.
25. National Cancer Institute. Tumor markers. November 4, 2015.
26. National Comprehensive Cancer Network (NCCN). NCCN guidelines for patients. Prostate cancer, Version 1.2016.
27. Pak k, Suh S, Hing H, Cheon G, Hahn S, et al. Diagnostic values of thyroglobulin measurement in fine-needle aspiration of lymph nodes in patients with thyroid cancer. *Endocrine*. September 2014: 70-77. doi:10.1007/s12020-014-0410-z.
28. Karlsen M, Hogdall C, Nedergaard L, Prahm K, Karlsen N, et al. HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelia ovarian cancer. *APMIS*. 2016; 124:1038-1045.
29. Yanwei Z, Bo J, Yuqing L, Rong L, Xueyan Z, et al. Serum carcinoembryonic antigen levels predicts the efficacy of EGFR-TKI in non-small cell lung cancer harboring EGFR mutations. *Cancer J*. March 2016; 12:254-258.
30. Lee M, Chang M, Yoo H, Lee K, Chay D, et al. Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer. *Yonsei Med J*. May 2016; 57(3):580-587.
31. Steffensen K, Waldstrom M, Brandslund I, Lun B, Sorensen S, et al. Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer. *Onco Lett*. May 6, 2016. doi: 10.3892/ol.201.4533.
32. Bird T, Dimitropoulou P, Turner R, Kenks S, Hey S, et al. Alpha-Fetoprotein Detection of Hepatocellular Carcinoma Leads to a Standardized Analysis of Dynamic AFP to Improve Screening Based Detection. *PLoS ONE*. June 2016; 11(6); 1-22. doi:10.1371/journal.pone.0156801.

33. Hogendorf P, Skulimowski A, Durczynski A, Kumor A, Poznanska G, et al. A Panel of CA19-9, Ca125, and Ca15-3 as the Enhanced Test for the Differential Diagnosis of the Pancreatic Lesion. *Hindawi*. 2017; 1-9. doi:10.1155/2017/8629712.

34. Cho Y, Jang H, Jang J, Kim T, Choe J, et al. Clinical outcomes of patients with hypercalcitoninemia after initial treatment for medullary thyroid cancer and postoperative serum calcitonin cutoffs for predicting structural recurrence. *Hed*. October 2016; 1501- 1508. doi:10.1002/hed.24469.